Journal for ImmunoTherapy of Cancer (Nov 2023)
873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models
Abstract
No abstracts available.